Shares of Advanced Enzyme Technologies Limited emerged as one of the top gainers on the NSE on May 11, surging 12.25% or ₹43.75 to ₹401 in early trade, touching an intraday high of ₹414.40 — which also marks a fresh 52-week high — after the company reported a strong set of audited consolidated results for FY26 featuring robust revenue and profit growth.
The stock opened sharply higher from its previous close of ₹357.25, with buying interest evident from the opening bell. At ₹401, Advanced Enzyme Technologies is trading near the top of its 52-week range of ₹251.95 to ₹414.40, reflecting a near-doubling from its 52-week low. Market capitalisation stands at approximately ₹4,503 crore. The trailing price-to-earnings ratio is 29.52 with a dividend yield of 1.30%. Average daily volume is around 2.53 lakh shares.
What did Advanced Enzyme Technologies report for FY26?
All figures converted from INR millions to crore (dividing by 10).
For the full year ended March 31, 2026, the company reported total income of ₹780.59 crore, up from ₹669.95 crore in FY25 — a growth of approximately 16.5%. Revenue from operations for the year stood at ₹745.76 crore against other income of ₹34.83 crore. Net profit for FY26 rose 29.6% to ₹173.61 crore from ₹133.97 crore in FY25, a strong improvement driven by operating leverage and an exceptional item credit of ₹11.36 crore. Profit before tax reached ₹232.54 crore. Total expenses for the year were ₹559.41 crore against ₹482.59 crore in FY25.
Total comprehensive income for FY26 surged to ₹268.42 crore from ₹152.80 crore in FY25, significantly boosted by other comprehensive income of ₹94.81 crore arising primarily from foreign currency translation differences of ₹93.81 crore — reflecting the company’s significant international operations and the impact of a weaker rupee on overseas subsidiary valuations.
How did Q4 FY26 perform?
The March quarter showed a sharp acceleration. Net profit for Q4 FY26 came in at ₹45.25 crore, up 69.2% year-on-year from ₹26.73 crore in Q4 FY25 and sequentially higher than ₹43.18 crore in Q3 FY26. Total income for the quarter was ₹210.60 crore, up from ₹175.92 crore in Q4 FY25 and ₹180.42 crore in Q3 FY26. Revenue from operations for the quarter stood at ₹203.37 crore. Profit before tax for Q4 was ₹59.80 crore, with total quarterly expenses of ₹150.90 crore.
The strong Q4 print — both on a year-on-year and sequential basis — suggests demand for the company’s enzyme products across human healthcare, animal nutrition, and food processing segments remained robust through the end of the fiscal year.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to consult a registered financial advisor before making any investment decisions. Business Upturn does not hold any position in the securities mentioned.